Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Barcode chip enables cheaper, faster blood testing

A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.

29 Dec 2008

Cancer is on the increase in Australia

The report shows that the number of new cancer cases diagnosed in Australia each year passed the 100,000 mark for the first time in 2005 and the number of new cases in 2008 is estimated to be over 108,000.

22 Dec 2008

Trial looks at high intensity focused ultrasound for locally recurrent prostate cancer

A Phase III clinical trial at New York University is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT) using the Sonablate(R) 500.

22 Dec 2008

Ingredient in cough medicine could treat prostate cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.

22 Dec 2008

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Oncothyreon Inc. announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately U.S. $13 million.

18 Dec 2008

Prostate cancer discovered in 40% of men who test negative for the disease

Forty percent of men with prostate cancer may not even know they have it, according to a new research study by the Prostate Cancer Foundation of Chicago.

16 Dec 2008

Low income men diagnosed more often with advanced prostate cancer

Coincident with the widespread adoption of PSA screening, the proportion of American men diagnosed with organ-confined, low risk prostate cancer has increased significantly during the last two decades. In a study scheduled for publication in the February 2009 issue of The Journal of Urology, researchers report that for low-income men, the opposite is true, with more men undiagnosed until their cancers had reached more advanced stages.

16 Dec 2008

USA's largest ever prostate cancer screening program shows high compliance and consistent results

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International .

15 Dec 2008

Gene subnetworks provide new prognostic markers for breast cancer

The metastasis or spread of breast cancer to other tissues in the body can be predicted more accurately by examining subnetworks of gene expression patterns in a patient's tumor, than by conventional gene expression microarrays, according to a presentation at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

15 Dec 2008

Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

15 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

New understanding on how the brain controls onset of puberty

A team of scientists from the University of Cambridge and the University of Cukurova in Turkey have taken a major step to understanding how the brain controls the onset of puberty.

12 Dec 2008

Neither vitamin E nor selenium reduce risk of prostate cancer

In perhaps the largest cancer chemoprevention trial ever conducted, researchers have found that supplementation with vitamin E or selenium, alone or in combination, was not associated with a lower risk of prostate cancer or other cancers.

10 Dec 2008

Vitamin C or E do not reduce prostate cancer, or other cancers risk

In a major cancer prevention study, long-term supplementation with vitamin E or C did not reduce the risk of prostate or other cancers for nearly 15,000 male physicians.

10 Dec 2008

Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers.

10 Dec 2008

UK's first prostate cancer patient treated using RapidArc radiotherapy

65-year-old grandfather of six, Graham McCormack has become the first cancer patient in the UK to be treated using RapidArc radiotherapy technology from Varian Medical Systems.

10 Dec 2008

Married men more likely to be screened for prostate cancer

Although the link between early screening and prostate cancer survival is well established, men are less likely to go for early screening unless they have a wife or significant other living with them, according to a study published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.

8 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly

More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.

3 Dec 2008

New insights into cellular senescence

Scientists have identified a molecular cause behind the ravages of old age and in doing so have also shown how a natural process for fighting cancer in younger persons can actually promote cancer in older individuals.

3 Dec 2008